Anke Hasselberg

Statistics

Publications

Citations

224

H-Index

Active since

2018

Affiliations

Novartis Institutes for BioMedical Research(Current)

Novartis (Switzerland)

Novartis (United States)

Anke Hasselberg is an author at Novartis Institutes for BioMedical Research specializing in medicine, psoriasis therapy, and interleukin 17 inhibition.

Publications per year

2018–2019

Publications

IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis

James G. Krueger, Keith A. Wharton, Thomas Schlitt et al. · Journal of Allergy and Clinical Immunology · 2019 · 188 citations

Medicine, Dermatology, Immunology +17

OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sjÖgren's syndrome

Thomas Dörner, Margit Zeher, Ute Laessing et al. · Annals of the Rheumatic Diseases · 2018 · 21 citations · Full text

Medicine, Immunology, Pharmacology +17

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis

Gerard Bruin, Anke Hasselberg, Julie Milojevic et al. · Clinical Pharmacology & Therapeutics · 2019 · 15 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

1–3 of 3